ANDA 201784, held by Rising. Cytarabine.
As of Nov 16, 2026, ANDA 201784 (Cytarabine), held by Rising, was first approved by FDA on Jan 30, 2012, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 30, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cytarabine100MG/ML · injectable;injection | Cytarabine | Rx |
| Dec 11, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 11, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 30, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters